Redeye provides a research update following the Q2 2024 report from Respiratorius.
Redeye provides a comment on the outcome in Respiratorius’ rights issue, announced earlier this afternoon.
Redeye provides a research update following the Q1 2024 report from Respiratorius.
Redeye finetunes its estimates following the Q4 2023 report from Respiratorius.
Redeye provides a retake of the investment case in Respiratorius following its Q3 2023 report and a change of lead analyst.
Redeye provides its outlook on Respiratorius following its Q2 2023 report.
Redeye leaves its comments on Respiratorius following its Q1 2023 report, which did not contain any significant surprises.
Redeye leaves its comments on Respiratorius following its Q3 report (split calendar year).
Redeye comments on Respiratorius following the release of its shortened fiscal year 2022 Q2 report.
Redeye comments on Respiratorius after its announcement of the preliminary data from the PK study with VAL001 and patent news from Japan.
Redeye comments on Respiratorius following the release of its shortened fiscal year report for the first quarter of 2022.
Redeye returns with an updated assessment of Respiratorius as its divestment of RCD405 and other COPD assets transform the company into a pu...
Redeye leaves its comment on Respiratorius following the year-end report.
Redeye leaves a comment on Respiratorious following the announcement of a SEK 45m fully guaranteed rights issue and the new plans for RCD405...
We make no valuation changes in the light of today's news that the EPO announced it intends to grant Respiratorius the patent application fo...
Redeye leaves a comment on Respiratorius following the Q2 report.
Redeye leaves a short comment following the capital injection of SEK 14,4m before transaction costs from warrants.
